斯丹赛生物技术有限公司（简称斯丹赛）定位于成为全球细胞治疗、干细胞治疗及再生医学领域的领导者，致力于服务科技创新和人类健康事业。作为全球CAR-T治疗领域的领军企业之一，斯丹赛已与全国多家知名三甲医院合作开展CAR-T临床试验，共完成了26例复发难治白血病的临床研究，其中23例病人达到完全缓解，完全缓解率达88%。Dedicated to innovative technology andhuman health and well-being, Innovative Cellular Therapeutics(ICT), aims tobecome the leader in cell therapy, stem cell therapy and regenerative medicinefield. As one of the leadersin CAR-T therapy across the world, ICT, through working in partnership withtop-ranking Chinese hospitals, conducted the CAR-T clinical trials on 26patients suffering from relapsed and refractory leukemia. 23 patients, 88% ofthe total trial population, have achieved complete remission after CAR-T therapytreatment.

为了进军海外市场，斯丹赛公司的英文名正式更改为Innovative CellularTherapeutics（网址：www.ictbio.com），简称ICT。ICT译意为创新细胞治疗，反映了斯丹赛要在国际细胞治疗领域不断取得创新性成果、造福人类健康的雄心。目前发展细胞治疗正当其时，欢迎大家加盟共创美好未来。                                                                               As part of the strategy on marketexpansion, SiDanSai (former name) officially changed its English name toInnovative Cellular Therapeutics (ICT) (www.ictbio.com),   indicatingICT’s vision of continuously making breakthroughs in global cell therapy and benefitinghuman wellness. At present, the development of cell therapy at the right time,welcome to join us for a better future.